Lenograstim
Lenograstim is a recombinant human granulocyte-colony stimulating factor (rhG-CSF). It is used to stimulate the production of white blood cells, specifically granulocytes, in the bone marrow. **Clinical Pearl:** In veterinary medicine, it is primarily used off-label to treat severe, life-threatening neutropenia associated with chemotherapy, parvovirus infection, or idiopathic neutropenia.
Mechanism: Activates proliferation and differentiation of **granulocyte progenitor cells** → enhances **granulopoiesis** (production of neutrophils and other granulocytes in the bone marrow).
Routes of administration
Contraindications
- Known hypersensitivity to G-CSF products
- Myeloid malignancies (unless specifically indicated)
Adverse effects
- Bone pain
- Fever
- Injection site reactions
- Splenomegaly (rare)
- Leukocytosis
Monitoring
- Complete Blood Count (CBC) with differential
- Neutrophil count
- Body temperature
Overdose
Excessive use may lead to severe leukocytosis. Treatment is supportive and involves discontinuing the drug or reducing the dose until white blood cell counts normalize.
VetSheet drug reference is intended for licensed veterinary professionals as a clinical decision-support aid, not a substitute for professional judgement or the manufacturer’s current label.